<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30475668</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1527-7755</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Jan</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
          <ISOAbbreviation>J Clin Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.</ArticleTitle>
        <Pagination>
          <StartPage>105</StartPage>
          <EndPage>114</EndPage>
          <MedlinePgn>105-114</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.18.00440</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE">Luminal breast cancer has a long natural history, with recurrences continuing beyond 10 years after diagnosis. We analyzed long-term follow-up (LTFU) of efficacy outcomes and adverse events in the Breast International Group (BIG) 1-98 study reported after a median follow-up of 12.6 years.</AbstractText>
          <AbstractText Label="PATIENTS AND METHODS">BIG 1-98 is a four-arm, phase III, double-blind, randomized trial comparing adjuvant letrozole versus tamoxifen (either treatment received for 5 years) and their sequences (2 years of one treatment plus 3 years of the other) for postmenopausal women with endocrine-responsive early breast cancer. When pharmaceutical company sponsorship ended at 8.4 years of median follow-up, academic partners initiated an observational, LTFU extension collecting annual data on survival, disease status, and adverse events. Information from Denmark was from the Danish Breast Cancer Cooperative Group Registry. Intention-to-treat analyses are reported.</AbstractText>
          <AbstractText Label="RESULTS">Of 8,010 enrolled patients, 4,433 were alive and not withdrawn at an LTFU participating center, and 3,833 (86%) had at least one LTFU report. For the monotherapy comparison of letrozole versus tamoxifen, we found a 9% relative reduction in the hazard of a disease-free survival event with letrozole (hazard ratio [HR], 0.91; 95% CI, 0.81 to 1.01). HRs for other efficacy end points were similar to those for disease-free survival. Efficacy of letrozole versus tamoxifen for contralateral breast cancer varied significantly over time (0- to 5-, 5- to 10-, and &gt; 10-year HRs, 0.62, 0.47, and 1.35, respectively; treatment-by-time interaction P = .005), perhaps reflecting a longer carryover effect of tamoxifen. Reporting of specific long-term adverse events seemed more effective with national registry than with case-record reporting of clinical follow-up.</AbstractText>
          <AbstractText Label="CONCLUSION">Efficacy end points continued to show trends favoring letrozole. Letrozole reduced contralateral breast cancer frequency in the first 10 years, but this reversed beyond 10 years. This study illustrates the value of extended follow-up in trials of luminal breast cancer.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ruhstaller</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>1 Kantonsspital St Gallen, St Gallen, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giobbie-Hurder</LastName>
            <ForeName>Anita</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>2 Dana-Farber Cancer Institute, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Colleoni</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>3 European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jensen</LastName>
            <ForeName>Maj-Britt</ForeName>
            <Initials>MB</Initials>
            <AffiliationInfo>
              <Affiliation>4 Rigshospitalet, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ejlertsen</LastName>
            <ForeName>Bent</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>4 Rigshospitalet, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Azambuja</LastName>
            <ForeName>Evandro</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>5 Institut Jules Bordet and L'Université Libre de Bruxelles, Brussels, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Neven</LastName>
            <ForeName>Patrick</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>6 KU Leuven, Leuven, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Láng</LastName>
            <ForeName>István</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>7 National Institute of Oncology, Budapest, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jakobsen</LastName>
            <ForeName>Erik Hugger</ForeName>
            <Initials>EH</Initials>
            <AffiliationInfo>
              <Affiliation>8 Lillebaelt Hospital, Vejle, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gladieff</LastName>
            <ForeName>Laurence</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>9 Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bonnefoi</LastName>
            <ForeName>Hervé</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>10 Université de Bordeaux, Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harvey</LastName>
            <ForeName>Vernon J</ForeName>
            <Initials>VJ</Initials>
            <AffiliationInfo>
              <Affiliation>11 Auckland City Hospital, Auckland, New Zealand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Spazzapan</LastName>
            <ForeName>Simon</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>12 CRO National Cancer Institute, Aviano, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tondini</LastName>
            <ForeName>Carlo</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>13 Ospedale Papa Giovanni XXIII, Bergamo, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Del Mastro</LastName>
            <ForeName>Lucia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>14 Ospedale Policlinico San Martino, Genoa, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Veyret</LastName>
            <ForeName>Corinne</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>15 Centre de Cancérolgie Henri Becquerel, Rouen, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Simoncini</LastName>
            <ForeName>Edda</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>16 ASST Spedali Civili di Brescia, Brescia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gianni</LastName>
            <ForeName>Lorenzo</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>17 Ospedale Infermi di Rimini, AUSL della Romagna, Ravenna, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rochlitz</LastName>
            <ForeName>Christoph</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>18 Universitätsspital, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kralidis</LastName>
            <ForeName>Elena</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>19 Kantonsspital, Aarau, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zaman</LastName>
            <ForeName>Khalil</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>20 University Hospital Vaud University Hospital Center, Lausanne, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jassem</LastName>
            <ForeName>Jacek</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>21 Medical University of Gdansk, Gdansk, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Piccart-Gebhart</LastName>
            <ForeName>Martine</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>5 Institut Jules Bordet and L'Université Libre de Bruxelles, Brussels, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Di Leo</LastName>
            <ForeName>Angelo</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>22 Hospital of Prato-AUSL Toscana Centro, Prato, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gelber</LastName>
            <ForeName>Richard D</ForeName>
            <Initials>RD</Initials>
            <AffiliationInfo>
              <Affiliation>2 Dana-Farber Cancer Institute, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>23 Harvard Medical School, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>24 Harvard TH Chan School of Public Health and Frontier Science and Technology Research Foundation, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Coates</LastName>
            <ForeName>Alan S</ForeName>
            <Initials>AS</Initials>
            <AffiliationInfo>
              <Affiliation>25 University of Sydney, Sydney, NSW, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>26 International Breast Cancer Study Group, Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goldhirsch</LastName>
            <ForeName>Aron</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>3 European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>26 International Breast Cancer Study Group, Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thürlimann</LastName>
            <ForeName>Beat</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>1 Kantonsspital St Gallen, St Gallen, Switzerland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>26 International Breast Cancer Study Group, Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Regan</LastName>
            <ForeName>Meredith M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>2 Dana-Farber Cancer Institute, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>23 Harvard Medical School, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT00004205</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>U24 CA075362</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Oncol</MedlineTA>
        <NlmUniqueID>8309333</NlmUniqueID>
        <ISSNLinking>0732-183X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>094ZI81Y45</RegistryNumber>
          <NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7LKK855W8I</RegistryNumber>
          <NameOfSubstance UI="D000077289">Letrozole</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>J Clin Oncol. 2019 Jun 10;37(17):1515-1516</RefSource>
          <PMID Version="1">31034298</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>J Clin Oncol. 2019 Jun 10;37(17):1516-1517</RefSource>
          <PMID Version="1">31034299</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077289" MajorTopicYN="N">Letrozole</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017698" MajorTopicYN="N">Postmenopause</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30475668</ArticleId>
        <ArticleId IdType="pmc">PMC6325353</ArticleId>
        <ArticleId IdType="doi">10.1200/JCO.18.00440</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation> Early Breast Cancer Trialists′ Collaborative Group (EBCTCG), Davies C, Godwin J, et al: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. 378: 771-784, 2011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3163848</ArticleId>
            <ArticleId IdType="pubmed">21802721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Early Breast Cancer Trialists′ Collaborative Group (EBCTCG), Pan H, Gray R, et al: 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377:1836-1846, 2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5734609</ArticleId>
            <ArticleId IdType="pubmed">29117498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>2005 Breast International Group (BIG) 1-98 Collaborative, Thürlimann B, Keshaviah A, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, </Citation>
        </Reference>
        <Reference>
          <Citation>2007 Breast International Group (BIG) 1-98 Collaborative, Coates AS, Keshaviah A, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492,</Citation>
        </Reference>
        <Reference>
          <Citation>2009 Breast International Group (BIG) 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, et al: Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361:766-776,</Citation>
        </Reference>
        <Reference>
          <Citation>Giobbie-Hurder A, Price KN, Gelber RD, et al. : Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials
6:272-287, 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2893024</ArticleId>
            <ArticleId IdType="pubmed">19528136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Regan MM, Price KN, Giobbie-Hurder A, et al. : Interpreting Breast International Group (BIG) 1-98: A randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Breast Cancer Res
13:209, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3218925</ArticleId>
            <ArticleId IdType="pubmed">21635709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Regan MM, Neven P, Giobbie-Hurder A, et al. : Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol
12:1101-1108, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3235950</ArticleId>
            <ArticleId IdType="pubmed">22018631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hudis CA, Barlow WE, Costantino JP, et al. : Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J Clin Oncol
25:2127-2132, 2007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17513820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curtis LH, Hammill BG, Eisenstein EL, et al. : Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care
45:S103-S107, 2007.  (10, Suppl 2)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17909367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirano K, Imbens GW: Estimation of causal effects using propensity score weighting: An application to data on right heart catheterization. Health Serv Outcomes Res Methodol
2:259-278, 2001</Citation>
        </Reference>
        <Reference>
          <Citation>Therneau TM, Grambsch PM: Modeling Survival Data: Extending the Cox Model. New York, NY, Springer-Verlag, 2000</Citation>
        </Reference>
        <Reference>
          <Citation>Cuzick J, Sestak I, Baum M, et al. : Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol
11:1135-1141, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21087898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morden JP, Alvarez I, Bertelli G, et al. : Long-term follow-up of the Intergroup Exemestane Study. J Clin Oncol
35:2507-2514, 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6175047</ArticleId>
            <ArticleId IdType="pubmed">28467729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derks MGM, Blok EJ, Seynaeve C, et al. : Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol
18:1211-1220, 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28732650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gnant M, Sestak I, Filipits M, et al. : Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: A combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Ann Oncol
26:1685-1691, 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25935792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sestak I, Cuzick J, Dowsett M, et al. : Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol
33:916-922, 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25332252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuzick J, Sestak I, Cawthorn S, et al. : Tamoxifen for prevention of breast cancer: Extended long-term follow-up of the IBIS-I Breast Cancer Prevention Trial. Lancet Oncol
16:67-75, 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4772450</ArticleId>
            <ArticleId IdType="pubmed">25497694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tannock IF: 10-year analysis of the ATAC trial: Wrong conclusion?
Lancet Oncol
12:216-217, author reply 217, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuzick J: Statistical controversies in clinical research: Long-term follow-up of clinical trials in cancer. Ann Oncol
26:2363-2366, 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4658544</ArticleId>
            <ArticleId IdType="pubmed">26433395</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
